Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone.

@article{Patelunas1991ComparativeAA,
  title={Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone.},
  author={D. Patelunas and William J. Carmint and J. Willis and Thomas Colatsky and Richard L. Fenichel},
  journal={Thrombosis research},
  year={1991},
  volume={62 5},
  pages={
          389-400
        }
}
The phosphodiesterase (PDE) inhibitors AY-31,390, milrinone and pelrinone (AY-28,768) were analyzed in human platelet aggregatory systems and in a rabbit arteriovenous shunt model to delineate their activity. AY-31,390 showed a remarkably potent capacity to inhibit human antithrombotic platelet aggregation. AY-31,390 inhibited arachidonic acid, U46619, collagen, epinephrine (second phase) and adenosine diphosphate (second phase) induced platelet aggregation (PA) with IC50 values of 0.18, 0.21… 
Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry
TLDR
Toborinone and olprinone inhibit human platelet aggregation, though these concentrations are higher than their therapeutic plasma concentrations, and the inhibitory effects of both drugs are related to the inhibition of bothCa2+ release and Ca2+ entry through [cAMP]i elevation.
Antithrombotic Effect of a New Glycoprotein IIb/IIIa Antagonist, SC-52012A: Studies in two Guinea-pig Thrombosis Models.
TLDR
Inhibitors of this receptor complex may prove to be effective for the control of arterial thrombosis as the expression of platelet membrane GPIIb/IIIa complex is the final step in the mechanism of platelets aggregation induced by most platelet agonists.
Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study.
Milrinone (MIL; a cAMP-specific phosphodiesterase type-III inhibitor), added in vitro to achieve concentrations below the therapeutic levels, inhibited agonist-induced platelet shape change (PSC).
Analysis of the potassium channel openers celikalim, pinacidil and cromakalim in platelet models of thrombosis.
TLDR
The greater antithrombotic activity of celikalim in vivo may be related to beneficial effects on blood rheology and reduced red blood cell deformability.
The Effect of Milrinone on Platelet Activation as Determined by TEG® Platelet Mapping™
TLDR
Therapeutic blood concentrations of milrinone exhibit a significant inhibitory effect on ADP and AA-induced platelet activation as determined by TEG Platelet Mapping, without affecting the conventional kaolin-activated TEG.
Disaggregatory effects of prostaglandin E 1 , amrinone and milrinone on platelet aggregation in human whole blood
Prostaglandin E 1 (PGE 1 ), amrinone and milrinone not only inhibit platelet aggregation, but also potentially induce disaggregation. We examined the disaggregatory effects of PGE 1 , amrinone and

References

SHOWING 1-10 OF 23 REFERENCES
Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade.
TLDR
Results demonstrate that, even though this dose of pelrinone elicited near maximal inhibition of platelet aggregation, the concurrent administration of an alpha 2-adrenergic antagonist was able to potentiate markedly the phosphodiesterase inhibitor antithrombotic activity.
Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
TLDR
It is demonstrated that plasma adenosine plays a crucial role in the antiaggregatory actions of HL 725 and several other inhibitors of cAMP PDE both in human and rat blood.
Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.
TLDR
An important role of plasma Ado is demonstrated in the antiplatelet activity of forskolin and this effect can be greatly potentiated by the clinically used drugs, dipyridamole and dilazep.
HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
TLDR
The new pyrimido-isoquinoline compound HL 725 is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine, higher than that of prostacyclin, the most active natural inhibitor of aggregation.
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
: Evaluation of a series of lactam heterocyclic analogues of cilostamide (2) as inhibitors of cyclic AMP phosphodiesterase derived from both human platelets and rat heart in comparison with their
Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.
TLDR
Several known phosphodiesterase inhibitor compounds that have been found useful in inhibiting platelet aggregation also inhibited the platelet low-Km cAMP phosphodiesters with potencies very similar to their antithrombotic effects.
Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats.
TLDR
The method seems to be associated with platelet aggregation and retention in rats, and suggests that KC-6141 is of value as antithrombotic drug in vivo.
DIPYRIDAMOLE AND OTHER PHOSPHODIESTERASE INHIBITORS ACT AS ANTITHROMBOTIC AGENTS BY POTENTIATING ENDOGENOUS PROSTACYCLIN
The antithrombotic effect of dipyridamole is through phosphodiesterase inhibition and depends on stimulation of platelet cyclic A.M.P. by circulating prostacyclin in the bloodstream. Low doses of
Adenosine metabolism in human whole blood. Effects of nucleoside transport inhibitors and phosphate concentration.
TLDR
Dilazep, NBMPR and dipyridamole were more effective in blocking Ado uptake and metabolism by erythrocytes suspended in a protein-free medium than by cells suspended in plasma, and Ado which slowly enters the cell was metabolized principally by Ado kinase rather than ADA.
The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets.
TLDR
Significant positive correlations were found between the radioactivity of 3':5'-cyclic AMP in platelets measured at the time of addition of the aggregating agent (ADP) and the extent to which the aggregation was inhibited.
...
1
2
3
...